Bladder cancer
Conditions
Interventions
50%, 
sections 
Gold Standard:Cystoscopic biopsy pathology
Index test:Sections 
of 
were 
pathologically 
examined, 
the 
tumor 
cell 
is 
Sponsors
Tongji Hospital Affiliated to Tongji University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The enrolled patients are patients with recurrent bladder cancer, and can obtain tissue samples and clinical relevant data that meet the needs of the trial, including but not limited to basic patient information, pathological information, imaging data, treatment information, and other follow-up information. 2. Bladder cancer confirmed by pathology, and a pathological report is retained; recurrence needs to be determined by imaging evaluation. 3. The sampled tumor tissue samples can meet the minimum sequencing requirements (at least 50mg for fresh surgical tissue, at least 2 for fresh puncture tissue; at least 10 FFPE white films for surgical samples, for FFPE white sheets made from puncture samples, at least 15 sheets are required), and the homogeneous quality control is qualified. 4. Complete clinical follow-up information before treatment and within 2 years after treatment.
Exclusion criteria
Exclusion criteria: 1. Participate in other research and affect the observation of this research; 2. The patient refuses to sign the informed consent; 3. The researcher believes that the subjects are not suitable for high-risk diseases or other special circumstances to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RNA-seq;SEN, SPE, ACC, AUC of ROC; | — |
Countries
China
Contacts
Public ContactLuo Huarong
Tongji Hospital Affiliated to Tongji University
Outcome results
None listed